In a related editorial, the authors comment that “although disappointing, the results of the DETERMINE study will inform ongoing and future development of immune checkpoint inhibitors for mesothelioma. As the roles of the multiple checkpoint receptors and their ligands become defined, understanding biomarker-defined patient populations that might benefit the most from these interventions will become imperative”.